|
Volumn 4, Issue 7, 2009, Pages 1051-1053
|
Meropenem-clavulanate: A new strategy for the treatment of tuberculosis?
|
Author keywords
lactamases; BlaC; Combination therapy; Mycobacterium tuberculosis; Tuberculosis
|
Indexed keywords
4 AMINOAZOBENZENE;
AMOXICILLIN PLUS CLAVULANIC ACID;
BETA LACTAM ANTIBIOTIC;
CARBAPENEM DERIVATIVE;
CEPHALOSPORIN DERIVATIVE;
CLAVULANIC ACID;
ETHAMBUTOL;
GATIFLOXACIN;
IMIPENEM;
ISONIAZID;
MEROPENEM;
MOXIFLOXACIN;
NITROCEFIN;
PENICILLIN G;
PIPERACILLIN PLUS TAZOBACTAM;
PYRAZINAMIDE;
RIFAMPICIN;
STREPTOMYCIN;
SULTAMICILLIN;
ANTIBIOTIC THERAPY;
BACTERIAL STRAIN;
CLINICAL TRIAL;
COMBINATION CHEMOTHERAPY;
DRUG MECHANISM;
DRUG POTENTIATION;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
MULTIDRUG RESISTANCE;
MYCOBACTERIUM TUBERCULOSIS;
PRIORITY JOURNAL;
SHORT SURVEY;
TUBERCULOSIS;
UNSPECIFIED SIDE EFFECT;
ANTITUBERCULAR AGENTS;
BETA-LACTAMASES;
CLAVULANIC ACID;
DRUG THERAPY, COMBINATION;
ENZYME INHIBITORS;
HUMANS;
MYCOBACTERIUM TUBERCULOSIS;
THIENAMYCINS;
TUBERCULOSIS;
|
EID: 67749118298
PISSN: 18607179
EISSN: 18607187
Source Type: Journal
DOI: 10.1002/cmdc.200900155 Document Type: Short Survey |
Times cited : (8)
|
References (10)
|